CORT113176 clinical trials
Also written CORT113176 and Dazucorilant.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses CORT113176 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses CORT113176 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Dazucorilant in Patients With Amyotrophic Lateral SclerosisActive, not recruitingPhase 2Corcept TherapeuticsNCT05407324Written as Dazucorilant 300 mg
- Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult ParticipantsCompletedPhase 1Corcept TherapeuticsNCT06495944Written as Dazucorilant
- Effects of Hepatic Impairment on the Pharmacokinetics of DazucorilantCompletedPhase 1Corcept TherapeuticsNCT06928779Written as Dazucorilant
- Single and Multiple Ascending Dose Study of CORT113176 in Healthy ParticipantsCompletedPhase 1Corcept TherapeuticsNCT04249323Written as CORT113176 Lipid Capsule Formulation
- Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male ParticipantsCompletedPhase 1Corcept TherapeuticsNCT04990310Written as [14C]-CORT113176
- Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy ParticipantsCompletedPhase 1Corcept TherapeuticsNCT04994743Written as CORT113176
Codes
What other systems call CORT113176 · ClinicalTrials.gg INT000804
- MeSH (NLM) C000623379CORT113176One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000623379 | CORT113176 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.